CTRI/2020/11/028806尚未招募未知
A Study to evaluate the effect of Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors on oxidative stress parameters in Type II Diabetes Mellitus Patients
Dr Ankita Sharma0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1.Patients aged between 30-60 years of either gender
- •2.Type II DM with a duration of disease >= 3 years.
- •3.HbA1c level 7.0-9.5%
- •4.Patients who are SGLT2i naïve patients.
- •5.Type II DM patients on a stable 2 or 3 drug combinations for the past 3 months. The allowed combination will be Metformin + Sulphonylurea +/- gliptins in the following dosages;
- •Metformin 1000-2500mg/day
- •Glipizide 5-40mg/day
- •Glimepride 1-8 mg/day
- •Gliclazide 30- 120mg/day
- •Sitagliptin 100mg/day
- •Linagliptin 5mg/day
- •Vildagliptin 50-100mg/day
- •Teneligliptin 20-40mg/day
- •6.Subjects who agree to comply with the study procedures
排除标准
- •1.History of hypersensitivity to the study drug.
- •2.Patients used glucagon-like peptide-1 agonists, or insulin in the past 12 weeks.
- •3.Patients with type 1 diabetes.
- •4.Subjects with history of liver disease (alanine aminotransferase, alkaline aminotransferase or alkaline phosphatase levels >3 times the upper limit of normal) or kidney disease (serum creatinine >1.1mg/dl)
- •5.History of chronic smoking or alcohol addiction.
- •6.Pregnant and lactating women
研究者
相似试验
招募中
不适用
The beneficial effects of newer antidiabetic drugs(Sodium Glucose Co-Transporters type 2) inhibitors for the treatment of raised blood glucose levelCTRI/2019/03/018307Jawaharlal Nehru Medical College and Hospital
尚未招募
不适用
An investigation into the effects of glucose and caffeine on multitasking, mood and fMRICognitive function in healthy adultsneural activation in healthy adultsAlternative and Complementary Medicine - Other alternative and complementary medicineMental Health - Studies of normal psychology, cognitive function and behaviourNeurological - Studies of the normal brain and nervous systemACTRN12612000202864GlaxoSmithKline Nutritional Healthcare40
已完成
不适用
Pleiotropic Effects and Safety of Sodium glucose co-transporter 2 inhibitor versus sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty LiverType 2 Diabetes and Non-alcoholic Fatty LiverJPRN-UMIN000020544Kanazawa university hospital Department of Disease Control and Homeostasis40
进行中（未招募）
不适用
Examination of the effect by taking the sodium glucose transporter 2 inhibitor everyday or only when a patient thinks it to be necessary for type 2 diabetes patients controlled inadequately.type 2 diabetes mellitusJPRN-UMIN000019253Toho University School of Medicine, Division of diabetes, metabolism and endocrinology50
尚未招募
不适用
The efficacy of sodium-dependent glucose co-transporter 2(SGLT2) inhibitors for pericardial fat in the type 2 diabetes patientsType 2 diabetes patients with pericardial fat is more than 125 mlJPRN-UMIN000020200ational Hospital Organization Takasaki General Medical Center30